Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial
Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial
复制标题
DOI：
10.1007/s11096-012-9710-7
复制
发表时间：
2013-02-01
影响因子：
2.4
通讯作者：
Ev, Lisiane Silveira
中科院分区：
文献类型：
--
作者：
Magalhaes Mourao, Aline Oliveira;Ferreira, Wandiclecia Rodrigues;Ev, Lisiane Silveira
背景巴西2型糖尿病患者需要采取措施改善血红蛋白A1 C水平，因为他们中约有73%的人血糖控制不佳。有证据表明，药物治疗计划对2型糖尿病患者有潜在的益处。目的探讨药学服务对2型糖尿病药物治疗后高血压患者血糖、血压和血脂的影响。巴西公共卫生系统的六个初级保健单位，欧罗普雷托，巴西。方法采用开放、随机、对照的临床试验方法，为期6个月。年龄在18岁或以上的受试者，正在使用口服降糖药物，血红蛋白A1 C水平为千分之七，随机分配到仅接受常规医疗保健或常规医疗保健加药物干预。主要结果指标血红蛋白A1 C。结果共纳入129例受试者，100例患者完成研究。与对照组（n = 50）相比，干预组（n = 50）显示血红蛋白A1 C（-0.6 vs 0.7%，p = 0.001）、空腹血糖、总胆固醇、LDL胆固醇、甘油三酯和收缩压显著降低，HDL胆固醇显著升高，并使用调脂剂和血小板聚集抑制剂。结论本研究表明，药学服务计划可能会提供重要的贡献，以降低血红蛋白A1 C的2型糖尿病患者。此外，在巴西的药物护理方案中，促进合理使用药物可能会更好地实现。
Background Brazilians with type 2 diabetes require action to improve haemoglobin A1C levels considering the fact that approximately 73 % of them have poor glycaemic control. Evidence has shown the potential benefits of pharmaceutical care programs in type 2 diabetes patients. Objective To evaluate the effect of a pharmaceutical care program on blood glucose, blood pressure and lipid profile in hyperglycaemic patients undergoing drug treatment for type 2 diabetes. Setting Six primary care units of the Brazilian public health system, Ouro Preto, Brazil. Method An open, randomised, controlled clinical trial was conducted for 6 months. Subjects aged 18 years or older who were using oral antidiabetic medications and presenting haemoglobin A1C levels a parts per thousand yen7 % were randomly assigned to receive only usual health care or usual health care plus pharmaceutical intervention. Main outcome measure Haemoglobin A1C. Results A total of 129 subjects were enrolled, and 100 patients completed the study. Compared to the control group (n = 50), the intervention group (n = 50) showed a significant reduction of haemoglobin A1C (-0.6 vs 0.7 %, p = 0.001), fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides and systolic blood pressure and a significant increase in HDL cholesterol and the use of lipid-modifying agents and platelet aggregation inhibitors. Conclusions This study suggests that a pharmaceutical care program may provide important contributions to reduce haemoglobin A1C in type 2 diabetes patients. Moreover, the promotion of the rational use of drugs may be better achieved in a context of pharmaceutical care programs in Brazil.